{"prompt": "['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'eTrack study number and', '204878 (ZOSTER-064)', 'Abbreviated Title', 'IND number', 'BB-IND-13857', 'Date of protocol', 'Administrative Change 3 Final: 11 February 2019', 'administrative change', 'Detailed Title', 'Observational study to assess frailty of subjects', 'during ZOSTER-006 and ZOSTER-022 and HZ', 'efficacy, immunogenicity and safety of HZ/su by', 'frailty status.', 'GSK Japan* study', 'representative name,', 'function and title', 'Signature', 'Date', '*(Administrative Change 3, 11 February 2019)', 'For internal use only', 'Checksum', '!Ver.!Created On', '-', '-', '70882527ffe6806e42bab9a20b06541dal1028ce 2.0 2/14/2019 1:02:54 PM -', '-', '11-FEB-2019', '7', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'Sponsor Information', '1. Sponsor', 'GlaxoSmithKline Biologicals', \"Rue de l'Institut 89, 1330 Rixensart, Belgium\", '2. Sponsor Medical Expert for the Study', 'Refer to the local study contact information document.', '3. Sponsor Study Monitor', 'Refer to the local study contact information document.', '11-FEB-2019', '8', '70882527ffe6806e42bab9a20b06541da11028ce']['CONFIDENTIAL', '204878 (ZOSTER-064)', 'Protocol Administrative Change 3 Final', 'SYNOPSIS', 'Detailed Title', 'Observational study to assess frailty of subjects during', 'ZOSTER-006 and ZOSTER-022 and HZ efficacy,', 'immunogenicity and safety of HZ/su by frailty status.', 'Objective(s)', 'Primary', 'To assess the baseline frailty of subjects enrolled in', 'ZOSTER-006 and ZOSTER-022.', 'Secondary', 'To present the distribution of SF-36 and EQ-5D scores in', 'subjects included in ZOSTER-006 and ZOSTER-022 at', 'b!aseline by country to allow comparison with normative', 'values for those questionnaires in the general population', 'of the countries participating in the study.', 'To assess vaccine efficacy against HZ by frailty status.', 'To assess HZ burden of illness (BOI) by frailty status.', 'To identify predictive factors for individuals developing', 'HZ.', 'To describe safety per frailty status.', 'To assess humoral immunogenicity by frailty status.', 'Tertiary', 'To describe CMI by frailty status of subjects enrolled in', 'ZOSTER-006 only.', 'Rationale for the', 'In the course of ZOSTER-006 and ZOSTER-022, QoL', 'study', 'questionnaires were encoded into the respective trial database', 'only for subjects who developed a suspected HZ episode', 'during the study. This was done to assess the QoL of subjects', 'who developed suspected cases of HZ between the vaccine', 'group and the placebo group. The remaining subjects who did', 'not develop suspected cases of HZ completed the', 'questionnaires; however, these questionnaires were never', 'encoded or analysed as part of ZOSTER-006 and ZOSTER-', '022. The purpose of this study is to allow for the encoding', 'and analysis of all questionnaires for subjects enrolled in', 'ZOSTER-006 and ZOSTER-022. The aim is to assess the', 'baseline frailty of subjects enrolled in ZOSTER-006 and', 'ZOSTER-022 and to investigate the representativeness of the', 'study population to the general population. Additionally,', 'analysis of efficacy, safety and immunogenicity will be', 'performed by frailty status. The study will also explore if', 'quality of life data and subject characteristics reported by the', 'subjects before the onset of HZ would be predictive of HZ.', '11-FEB-2019', '9', '70882527ffe6806e42bab9a20b06541da11028ce']\n\n###\n\n", "completion": "END"}